Introduction {#s1}
============

Chronic kidney disease (CKD) is increasingly common in the US and worldwide [@pmed.1001344-Coresh1],[@pmed.1001344-Zhang1]. Related complications, including end-stage renal disease (ESRD) and cardiovascular disease (CVD), have major public health and economic implications [@pmed.1001344-Coresh1]--[@pmed.1001344-Khan1]. Screening for CKD has been somewhat controversial in the absence of direct evidence from a randomized clinical trial [@pmed.1001344-Fink1]. However, early identification of individuals with CKD, especially targeting populations with a high risk for CKD and related adverse outcomes [@pmed.1001344-Uhlig1], followed by the implementation of evidence-based interventions can slow or prevent the progression to advanced stages of the disease, reduce the risk of CVD and other complications of decreased glomerular filtration rate (GFR), and improve survival and quality of life [@pmed.1001344-Levey1]. However, large proportions of individuals with CKD remain undiagnosed and, as a consequence, are not benefiting from those interventions. For instance, in the US, awareness of CKD in the general population remains very low [@pmed.1001344-Coresh1]. During the 1999--2004 period, the proportion of US adults with stage 3 CKD who reported being aware of their status was only 11.6% in men and 5.5% in women. Even among men with stage 3 CKD and elevated albuminuria, awareness of weak or failing kidneys was only 22.8%. Among those with stage 4 CKD, the corresponding percentage was 42% for both men and women [@pmed.1001344-Coresh1]. In clinical settings, awareness levels are also low. Data from the US National Kidney Foundation\'s Kidney Early Evaluation Program, for the 2000--2009 period, indicate that only 9% of patients with CKD are aware of their diagnosis [@pmed.1001344-WhaleyConnell1].

Strategies for early identification and treatment of people with CKD are therefore needed worldwide. The use of complex and potentially expensive detection strategies may prevent those at risk from deriving the benefits of preventative interventions, especially in settings where renal replacement therapy is not readily available. Several risk factors that are independently associated with the occurrence of CKD and easily assessable in routine clinical settings have been incorporated in model equations for predicting the occurrence of CKD or progression in people already diagnosed with CKD. These models have utility even in the context of automatic reporting of the estimated GFR (eGFR). Indeed, recent data indicate that referral to a nephrologist by primary care physicians as the result of making eGFR available mostly occurs for certain subgroups in the population (women and elderly), and a high proportion of referrals are inappropriate [@pmed.1001344-Akbari1].

The use of risk models is very attractive and likely cost-effective for large-scale CKD risk stratification, and would allow the identification of all the segments of the population that would benefit the most from CKD detection. To this end, it is very important that existing models are not methodologically flawed, and that they provide accurate estimates of the CKD risk in different populations.

To date, there has been no effort, to our knowledge, to provide decision makers and healthcare providers with a balanced account of the performance of existing CKD risk models. We therefore systematically reviewed studies of risk equations to predict CKD or its progression, with the objectives of summarizing evidence on their performance and exploring methodological issues surrounding their development and validation and application.

Methods {#s2}
=======

We performed literature searches to identify all risk models developed to predict the presence/occurrence of CKD, or to predict the progression of CKD in those with the disease. We also searched for all studies that applied existing CKD risk models either in the population from which the model was developed or in different populations, and, lastly, we searched for all impact studies and clinical practice guidelines that incorporated existing CKD risk models.

Model Development and Validation Studies {#s2a}
----------------------------------------

### Data sources and search strategy {#s2a1}

We searched the PubMed MEDLINE and Embase databases from 1 January 1980 to 20 June 2012, for English- or French- language studies of CKD risk prediction model development and/or validation. We used a combination of search terms related to CKD and prediction. The search strategies are provided in detail in Texts S2 and S3. In addition, we manually searched the reference lists of eligible studies and relevant reviews, and traced studies that had cited them through the ISI Web of Science to find additional published and unpublished data.

### Study selection {#s2a2}

Two evaluators (J. B. E. and A. P. K.) independently identified articles and sequentially screened them for inclusion ([Figure 1](#pmed-1001344-g001){ref-type="fig"}). Where necessary, the full text of articles and/or supplemental materials (tables and appendices) was reviewed before deciding on inclusion. Disagreements were solved by consensus between both authors.

![Article selection process.](pmed.1001344.g001){#pmed-1001344-g001}

Eligible articles had to report a risk assessment tool (equation and/or score) for predicting CKD or its progression, derived in adult human populations. Reporting of quantitative measures of the performance of tools was preferable, but not necessary for inclusion. The reported metrics of evaluation of predictive ability could be the area under the receiver operating characteristic curve (AUC) or C-statistic, reclassification percentage, net reclassification improvement (NRI), or integrated discrimination improvement index (IDI). These metrics are recognized and used for the assessment of prediction models [@pmed.1001344-Moons1],[@pmed.1001344-Moons2]. We excluded studies that reported only measures of association between risk factors and CKD without information on the beta coefficients of variables included in a prediction equation, and simulation studies.

### Data extraction and quality assessment {#s2a3}

Two reviewers (J. B. E. and A. P. K.) independently conducted the data extraction and quality assessment. We did not use a particular framework for quality assessment, as there is no consensus on a quality assessment framework for risk prediction models. Consequently, we did not develop a formal protocol for the review ([Text S1](#pmed.1001344.s003){ref-type="supplementary-material"}). From each study, we extracted data on study design, setting, population characteristics, the number of patients in the derivation and validation cohorts, the number of participants with the outcome of interest, the number of candidate variables tested as predictors, and the number and list of those variables included in the final model, as well as the type of statistical model used. For the discriminative performance of models, we extracted information on the AUC or C-statistic, which indicates the ability of a risk model to rank-order individuals\' risks. To describe model calibration, we extracted data on the difference between the observed and predicted rates of CKD, as well as the *p*-value of the corresponding test statistic. Measures of calibration assess the ability of a risk prediction model to predict accurately the absolute level of risk that is subsequently observed.

For the assessment of reclassification, we extracted the NRI and IDI values, and the accompanying 95% CIs and *p*-values, when available. Reclassification analyses generally indicate the proportion of individuals who are reclassified from one risk stratum (based on estimated risk provided from a first model) to a different risk stratum (based on estimated risk from a different model, or a model that has additional variables compared with the first model). The IDI measures the extent to which the use of a new risk marker correctly revises upward the predicted risk of individuals who experienced the event of interest and correctly revises downward the predicted risk of individuals who did not experience the event.

### Data synthesis {#s2a4}

Given the wide range of metrics used for the assessment of the predictive ability of CKD risk models, and the heterogeneity in both the risk factors used for prediction and their number, as well as the study designs, we opted to conduct a narrative synthesis of the evidence instead of a meta-analysis.

Impact Studies and Implementation of Risk Models in Guidelines {#s2b}
--------------------------------------------------------------

Impact studies were captured by (1) scanning those publications identified through the search strategy for model development and validation, and (2) applying the search strategy for impact studies proposed by Reilly and Evans [@pmed.1001344-Reilly1], which combines the model\'s acronym, name of the cohort, or first author with a specific search term ([Text S3](#pmed.1001344.s005){ref-type="supplementary-material"}). We searched relevant clinical practice guidelines to investigate the implementation of CKD prediction models in countries in which such models have been developed. In the absence of validated strategies for these types of searches, we targeted guidelines (when available in English language) compiled by a selection of organizations known to be involved in issues relating to kidney diseases, including the American Society of Nephrology (<http://www.asn-online.org>), the US National Kidney Foundation [@pmed.1001344-National1], the UK National Institute for Health and Clinical Excellence [@pmed.1001344-National2], the International Society of Nephrology [@pmed.1001344-International1], the European Renal Association--European Dialysis and Transplant [@pmed.1001344-Heemann1], the Canadian Society of Nephrology [@pmed.1001344-Canadian1], Kidney Disease: Improving Global Outcomes [@pmed.1001344-Kidney1], The Korean Society of Nephrology (<http://www.ksn.or.kr/english/>), the Japanese Society for Dialysis Therapy [@pmed.1001344-Japanese1], The Japan Association of Chronic Kidney Disease Initiatives (J-CKDI) [@pmed.1001344-Imai1], and the Taiwan Society of Nephrology [@pmed.1001344-Taiwan1].

Results {#s3}
=======

[Figure 1](#pmed-1001344-g001){ref-type="fig"} describes the study selection process. Of the citations identified through searches, 210 abstracts were selected for in-depth evaluation, and 46 full-text publications were reviewed. After all exclusions, 26 articles, reporting on 30 CKD prediction risk scores and 17 CKD progression risk scores, met the eligibility criteria and were included in the review.

CKD Prediction Risk Scores {#s3a}
--------------------------

[Table 1](#pmed-1001344-t001){ref-type="table"} summarizes data from studies that developed CKD risk prediction models. Five of the 30 CKD risk prediction models were developed using cross-sectional data (thus, prevalent CKD) [@pmed.1001344-Bang1]--[@pmed.1001344-Kwon1], and the remaining models were based on cohort studies.
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###### Development of risk models for predicting chronic kidney disease.

![](pmed.1001344.t001){#pmed-1001344-t001-1}

  Study                                                                                             Country/Ethnicity                            Design/Setting              Candidate Variables (*n*)                                                                     Risk factors included                                                                                             *n* Total/*n* Outcomes                            Age (Years)                                                                                                 Outcomes Predicted                                                                                               Time Horizon (Years)[a](#nt102){ref-type="table-fn"}                                  Discrimination AUC                                                         Calibration                          Method of Internal Validation   Type of Model
  ----------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------- ---------------
  Bang et al. 2007 [@pmed.1001344-Bang1]---SCORED score                                                  US/mixed                       Cross-sectional/population-based                24                                                               Age, sex, anemia, HTN, diabetes, Hx of CVD, Hx of CHF, PVD                                                                                8,530/601                                      20--85                                                                                     CKD (GFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                          NA                                                                  0.88                                                                     NR                                        Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.88                                                                     NR                                      Split-sample           
  Kshirsagar et al. 2008 [@pmed.1001344-Kshirsagar1]---ARIC/CHS score 1                             US/white and black                Prospective cohort/population-based               19                                                                 Age, anemia, sex, HTN, diabetes, PVD, Hx of CHF or CVD                                                                                 9,470/1,605                                     45--64                                                                                     CKD (GFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         4--9                                                                 0.69                                                             HL test (*p*\>0.2)                                Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.68                                                                     NR                                      Split-sample           
  Kshirsagar et al. 2008 [@pmed.1001344-Kshirsagar1]---ARIC/CHS score 2                             US/white and black                Prospective cohort/population-based               19                                                            Age, anemia, sex, HTN, diabetes, low HDL, PVD, Hx of CHF or CVD                                                                             9,470/1,605                                     45--64                                                                                     CKD (GFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         4--9                                                                 0.70                                                             HL test (*p*\>0.2)                                Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.70                                                                     NR                                      Split-sample           
  Fox et al. 2010 [@pmed.1001344-Fox1]---Framingham score 1                                              US/white                     Prospective cohort/population-based               NR                                                                                        Age, sex                                                                                                         2,345/213                                    Mean: 56.6                                                                                   CKD (GFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         9.5                                                                  0.776                                                       HL χ^2^ = 8.20 (*p* = 0.41)                            Apparent                Logistic
  Fox et al. 2010 [@pmed.1001344-Fox1]---Framingham score 2                                          US/mainly white                  Prospective cohort/population-based               NR                                                         Age, sex, SBP, HTN, HTN treatment, smoking, BMI, HDL, diabetes, eGFR,                                                                           2,345/213                                    Mean: 56.6                                                                                    CKD (GFR\<60 ml/min/1.73 m2)---MDRD equation                                                                                                          9.5                                                                  0.81,                                                       HL χ^2^ = 2.98 (*p* = 0.94)                            Apparent                Logistic
  Fox et al. 2010 [@pmed.1001344-Fox1]---Framingham score 3                                          US/mainly white                  Prospective cohort/population-based               NR                                            Age, sex, SBP, HTN, HTN treatment, smoking, BMI, HDL, diabetes, eGFR, aldosterone, homocysteine                                                              2,345/213                                    Mean: 56.6                                                                                   CKD (GFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         9.5                                                                  0.82                                                        HL χ^2^ = 3.48 (*p* = 0.90)                            Apparent                Logistic
  Hippisley-Cox and Coupland 2010 [@pmed.1001344-HippisleyCox1]---QKidney score        UK/mixed: white, black, South-Asian, Chinese   Prospective cohort//population-based              18               Age, ethnicity, deprivation, smoking, BMI, SBP, diabetes, rheumatoid arthritis, CVD, treated HTN, CHF, PVD, NSAID use, family Hx of KD, SLE, kidney stones   1,591,884 (775,091 women and 799,658 men)/23,786 (CKD); 1,266 (ESRD)        35--74        Moderate-severe CKD (kidney transplant, dialysis, nephropathy, persistent proteinuria, or eGFR\<45 ml/min/1.73 m^2^) and ESRD (kidney transplant, dialysis, or eGFR\<15 ml/min/1.73 m^2^)---MDRD equation                            5                                   CKD stage: 0.88, men; 0.88, women/ESRD stage: 0.85, men; 0.84, women                                     NR                                        Apparent                   Cox
  Chien et al. 2010 [@pmed.1001344-Chien1]---Taiwan score 1                                           Taiwan/Chinese                  Prospective cohort/population-based               12                                                                           Age, BMI, DBP, Hx of T2DM, stroke                                                                                             5,168/190                                    Mean: 51.2                                                                             CKD (GFR reduced but ≥ 60 ml/min/1.73 m^2^)---MDRD equation                                                                                                   4                                                                   0.77                                                            HL test (*p*\>0.10).                               Apparent                   Cox
  Chien et al. 2010 [@pmed.1001344-Chien1]---Taiwan score 2                                           Taiwan/Chinese                  Prospective cohort/population-based               12                                                 Age, BMI, DBP, Hx of T2DM, stroke, uric acid, postprandial glucose, HbA1c, proteinuria                                                                  5,168/190                                    Mean: 51.2                                                                              CKD (GFR reduced but ≥ 60 ml/min/1.73 m2)---MDRD equation                                                                                                    4                                                                   0.77                                                            HL test (*p*\>0.10)                                Apparent                   Cox
  Halbesma et al. 2011 [@pmed.1001344-Halbesma1]---PREVEND score                                    Netherlands/white                 Prospective cohort/population-based               18                                                               Age, urinary albumin excretion, SBP, CRP, known HTN, eGFR                                                                                 6,809/272                                      28--75                                          CKD (the most renal function decline \[top 20% of the total population\] and eGFR\<60 ml/min/1.73 m^2^ at follow-up)---MDRD equation                                                              6.4                                                                  0.84                                                                     NR                                        Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.84                                                                     NR                                        Bootstrap            
  Ando et al. 2011 [@pmed.1001344-Ando1]---Japan/HIV score                                             Japan/Asian                      Prospective cohort/clinic-based                  8                                                                      Age, CD4 count, diabetes, proteinuria, eGFR                                                                                  534 (HIV patients)/18                                20--81                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         1                                                                   0.84                                                                     NR                                        Apparent                Logistic
  Blech et al. 2011 [@pmed.1001344-Blech1]---Israel score 1                                            Israel/white                       Cross-sectional/clinic-based                  NR                                                                    Age, sex, ethnicity, diabetes type and duration                                                                                      1,274/556                                    Mean: 62.6                     Diabetic nephropathy (microalbuminuria \[0.03--0.3 g/g creatinine\], proteinuria \[\>0.3 g/g creatinine\]), or dialysis in the absence of any other unrelated renal disease                                           NA                                                                  0.58                                                                     NR                                        Apparent                Logistic
  Blech et al. 2011 [@pmed.1001344-Blech1]---Israel score 2                                            Israel/white                       Cross-sectional/clinic-based                  NR                                      Five SNPs in five genes (HSPG2, NOS3, ADIPOR2, AGER, CCL5), age, sex, ethnicity, diabetes type and duration                                                        1,274/556                                    Mean: 62.6                     Diabetic nephropathy (microalbuminuria \[0.03--0.3 g/g creatinine\], proteinuria \[\>0.3 g/g creatinine\]), or dialysis in the absence of any other unrelated renal disease                                           NA                                                                  0.67                                                                     NR                                        Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.63                                                                     NR                                      Split-sample           
  Thakkinstian et al. 2011 [@pmed.1001344-Thakkinstian1]---Thailand score                             Thailand/Asian                    Cross-sectional/population-based                16                                                                        Age, diabetes, HTN, Hx of kidney stones                                                                                          3,459/606                                       ≥18                                                                                       CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         NA                                                                  0.77                                                Bias observed versus predicted values: 0.045                   Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.74.                                                                    NR                                        Bootstrap            
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha1]---Framingham score 3a                               US/white                     Prospective cohort/population-based               NR                                                      Age, sex, cohort status, baseline eGFR, HTN, diabetes, proteinuria, 16 SNPs                                                                        2,489/270                                      28--62                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                                                       0.780, without genotype score; 0.781, with genotype score (difference: *p* = 0.2)                              NR                                        Apparent                Logistic
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha1]---Framingham score 3b                           US/mainly white                  Prospective cohort/population-based               NR                                                                                   Age, sex, 16 SNPs                                                                                                     2,489/270                                      28--62                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         10                            0.748, without genotype score; 0.751, with genotype score (difference: *p* = 0.3)                              NR                                        Apparent                Logistic
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha2]---Framingham score 4a                           US/mainly white                  Prospective cohort/population-based               NR                                                                                   Age, diabetes, HTN                                                                                                    2,490/229                                      45--64                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         10                                                                  0.79.                                                                    NR                                        Apparent                Logistic
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha2]---Framingham score 4b                           US/mainly white                  Prospective cohort/population-based               NR                                                                           Age, diabetes, HTN, eGFR category                                                                                             2,490/229                                      45--64                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         10                                                                  0.81                                                                     NR                                        Apparent                Logistic
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha2]---Framingham score 4c                           US/mainly white                  Prospective cohort/population-based               NR                                                                     Age, HTN, diabetes, baseline eGFR, albuminuria                                                                                      2,490/229                                      45--64                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         10                                                                  0.81                                                        HL χ^2^ = 7.27; (*p* = 0.60)                           Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.79                                                                     NR                                        Bootstrap            
  Alssema et al. 2012 [@pmed.1001344-Alssema1]---Rotterdam-Hoorn score                              Netherlands/white                 Prospective cohort/population-based                9                     Age, BMI, waist circumference, HTN treatment, current smoking, parent and/or sibling with CVD (age\<65 y), parent and/or sibling with diabetes                                      6,019/366                                      28--85                                                                                     CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         7                                                          0.82, men; 0.81, women                                 HL χ^2^ = 7.6 (*p* = 0.48), men; 6.3 (*p* = 0.62), women             Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                0.80, men; 0.82, women                                                                                                      Bootstrap            
  Kwon et al. 2012 [@pmed.1001344-Kwon1]---Korean risk score                                           Korea/Asian                      Cross-sectional/population-based                16                                                                   Age, sex, anemia, HTN, diabetes, CVD, proteinuria                                                                                     6,565/100                                       ≥19                                                                                       CKD (eGFR\<60 ml/min/1.73 m^2^)---MDRD equation                                                                                                         NA                                                                  0.83                                                                     NR                                        Apparent                Logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.87                                                                     NR                                      Split-sample           
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Major Final model                      20 countries/multi-ethnic             Prospective cohort/population-based               21                                                Sex, eGFR, ACR, SBP, HbA1c, diabetic retinopathy, age at completion of formal education                                                                  11,140/166                                Mean: 66 (SD: 6)                                               Doubling of serum creatinine to ≥2.26 mg/dl (≥200 µmol/l), renal replacement therapy, or renal death in diabetes                                                                         5                                                                   0.87                                                         HL χ^2^ = 1.5 (*p* = 0.9)                             Bootstrap                  Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Major eGFR model                       20 countries/multi-ethnic             Prospective cohort/population-based                1                                                                                          eGFR                                                                                                           11,140/166                                Mean: 66 (SD: 6)                                               Doubling of serum creatinine to ≥2.26 mg/dl (≥200 µmol/l), renal replacement therapy, or renal death in diabetes                                                                         5                                                                   0.78                                                                     NR                                        Apparent                   Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Major ACR model                        20 countries/multi-ethnic             Prospective cohort/population-based                1                                                                                          ACR                                                                                                            11,140/166                                Mean: 66 (SD: 6)                                               Doubling of serum creatinine to ≥2.26 mg/dl (≥200 µmol/l), renal replacement therapy, or renal death in diabetes                                                                         5                                                                   0.75                                                                     NR                                        Apparent                   Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Major eGFR+ACR model                   20 countries/multi-ethnic             Prospective cohort/population-based                2                                                                                       eGFR, ACR                                                                                                         11,140/166                                Mean: 66 (SD: 6)                                               Doubling of serum creatinine to ≥2.26 mg/dl (≥200 µmol/l), renal replacement therapy, or renal death in diabetes                                                                         5                                                                   0.82                                                         HL χ^2^ = 6.1 (*p* = 0.7)                             Apparent                   Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Albuminuria Final model                20 countries/multi-ethnic             Prospective cohort/population-based               21                                               Ethnicity, eGFR, ACR, SBP, HTN treatment, HbA1c, diabetic retinopathy, waist circumference                                                               7,377/2,715                                Mean: 66 (SD: 6)                                                                                       New-onset albuminuria in diabetes                                                                                                                5                                                                   0.65                                                        HL χ^2^ = 16.5 (*p* = 0.06)                            Bootstrap                  Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Albuminuria eGFR model                 20 countries/multi-ethnic             Prospective cohort/population-based                1                                                                                          eGFR                                                                                                          7,377/2,715                                Mean: 66 (SD: 6)                                                                                       New-onset albuminuria in diabetes                                                                                                                5                                                                   0.54                                                                     NR                                        Apparent                   Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Albuminuria ACR model                  20 countries/multi-ethnic             Prospective cohort/population-based                1                                                                                          ACR                                                                                                           7,377/2,715                                Mean: 66 (SD: 6)                                                                                       New-onset albuminuria in diabetes                                                                                                                5                                                                   0.63                                                                     NR                                        Apparent                   Cox
  Jardine et al. 2012 [@pmed.1001344-Jardine1]---ADVANCE Albuminuria eGFR+ACR model             20 countries/multi-ethnic             Prospective cohort/population-based                2                                                                                       eGFR, ACR                                                                                                        7,377/2,715                                Mean: 66 (SD: 6)                                                                                       New-onset albuminuria in diabetes                                                                                                                5                                                                   0.63                                                        HL χ^2^ = 78.1 (*p*\<0.001)                            Apparent                   Cox

ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; ARIC, Atherosclerosis Risk in Communities Study; BMI, body mass index; CHF, congestive heart failure; CHS, Cardiovascular Health Study; CRP, c-reactive protein; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; HL, Hosmer-Lemeshow; HTN, hypertension; Hx, history; KD, kidney disease; NA, not applicable; NR, not reported; NSAID, nonsteroidal anti-inflammatory drug; PVD, peripheral vascular disease; SBP, systolic blood pressure; SD, standard deviation; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism; T2DM, type 2 diabetes mellitus;.

Time horizon is the time over which the prediction of outcomes is made, and is the duration of follow-up in each study unless specified otherwise.

### Populations, outcomes, and risk factors {#s3a1}

The majority of the 30 CKD risk models were developed from samples that mostly included white individuals, and only four studies included exclusively Asian participants [@pmed.1001344-Thakkinstian1]--[@pmed.1001344-Ando1]. The number of participants included in the studies ranged from 534 to 1.6 million, and their ages ranged from 18 to 90 y. The length of follow-up in the cohort studies ranged from 1 to 10 y.

The definition of CKD was fairly consistent across prediction models (eGFR\<60 ml/min/1.73 m^2^), although nine models focused on predicting diabetic nephropathy [@pmed.1001344-Blech1], and another on CKD prediction among HIV-positive individuals [@pmed.1001344-Ando1]. The included risk models used the Modification of Diet in Renal Disease (MDRD) Study equation to estimate GFR, with the exception of models from the ADVANCE study [@pmed.1001344-Jardine1], which used estimates from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The original MDRD equation is eGFR (ml/min/1.73 m^2^) = 175×standardized Scr (mg/dl)^−1.154^×age (y)^−0.203^×1.212 \[if black\]×0.742 \[if female\], where Scr is serum creatinine [@pmed.1001344-Levey2]. The less used CKD-EPI equation is eGFR (ml/min/1.73 m^2^) = 141×min(Scr/κ, 1)^α^×max(Scr/κ, 1)^−1.209^× 0.993^age^×1.018 \[if female\]×1.159 \[if black\], where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1 [@pmed.1001344-Levey3].

Ten studies provided usable data on the numbers of candidate variables tested for inclusion in the models. This number ranged from one to 24, giving conservative estimates of the ratio of the number of observed events (outcome of interest) to the number of candidate variables ranging from six to 166. The predictors most commonly included in the final prediction models were age, sex, body mass index, diabetes status, systolic blood pressure, serum creatinine, a measure of proteinuria, and serum albumin or total protein ([Table S1](#pmed.1001344.s001){ref-type="supplementary-material"}). Three studies used novel biomarkers or genetic or circulating factors [@pmed.1001344-Blech1],[@pmed.1001344-Fox1],[@pmed.1001344-OSeaghdha1]. Eighteen models were derived using logistic regressions, and three using Cox regressions. All studies reported the original model with beta coefficients, and five studies presented additional point-based scoring systems [@pmed.1001344-Bang1],[@pmed.1001344-Jardine1],[@pmed.1001344-OSeaghdha2], or risk calculators [@pmed.1001344-Tangri1],[@pmed.1001344-HippisleyCox1].

### Performance of risk prediction models {#s3a2}

[Table 1](#pmed-1001344-t001){ref-type="table"} shows the performance of the various CKD risk models. All the included studies reported a C-statistic ranging from 0.57 to 0.88, indicating a modest-to-good discriminatory performance. Nine risk scores were internally validated, through split-sample validation in four cases (three of these were also externally validated), and bootstrapping in five other studies. Twelve risk models had an estimate of calibration: Hosmer-Lemeshow test statistics in most cases, which generally indicated good calibration.

### CKD model improvement {#s3a3}

Four studies assessed model improvement subsequent to adding extra variables. One study reported a significant improvement after adding circulating biomarkers (aldosterone and homocysteine) to traditional CKD risk factors [@pmed.1001344-Fox1]; the difference in AUC was 0.012 (*p* = 0.00233), NRI 6.9% (*p* = 0.0004), and IDI 0.013 (*p* = 0.004). The second study reported an AUC difference of 0.001 (*p* = 0.2) for adding genotypic information (16 single nucleotide polymorphisms) to known risk factors [@pmed.1001344-OSeaghdha1]. The third study reported no statistically significant improvement from adding uric acid, postprandial glucose, hemoglobin A~1c~, and proteinuria ≥ 100 mg/dl to traditional risk factors, with nonsignificant differences in AUC (−0.003), NRI (−0.0889), and IDI (0.0141) [@pmed.1001344-Chien1]. The last study found that a model for predicting major renal events using eGFR and albumin/creatinine ratio (ACR) (AUC: 0.818) was superior to models with either of the predictors alone (AUC: 0.779 for eGFR, and 0.752 for ACR); all three models were inferior to an expanded model with five additional variables (AUC: 0.847) (all *p*\<0.05 for AUC comparison) [@pmed.1001344-Jardine1]. In the same study, the eGFR+ACR (AUC: 0.629) and ACR alone (AUC: 0.627) models had similar performance for predicting new-onset albuminuria; both were superior to the eGFR alone model (AUC: 0.543) (both *p*\<0.05), while all three were inferior to an extended model (AUC: 0.647) with six extra variables (all *p*\<0.05 for AUC comparison) [@pmed.1001344-Jardine1].

### Validation of CKD risk prediction models {#s3a4}

[Table 2](#pmed-1001344-t002){ref-type="table"} shows the results of the external validation of CKD risk models. Only eight of the models were externally validated. Of these, only four models were validated more than once: twice for three models [@pmed.1001344-Chien1],[@pmed.1001344-HippisleyCox1]--[@pmed.1001344-Collins1] and three times for one model [@pmed.1001344-Bang1],[@pmed.1001344-Bang2],[@pmed.1001344-Bang3]. The AUC in validation studies (0.57 to 0.88) was generally lower than that in the derivation sample; the change from the original C-statistic from when the model was first derived ranged from −0.2 to +0.06 ([Table 2](#pmed-1001344-t002){ref-type="table"}), being negative or null except in two cases of validation of one score where it was positive [@pmed.1001344-Chien1], thus indicating a generally lower discrimination in validation populations. In the validation populations, the calibration was also poorer, though it was not assessed in most of validation studies.

10.1371/journal.pmed.1001344.t002

###### External validation of risk prediction models for chronic kidney disease.
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  Study                                                            Name of the Model Validated            Validation Population/Country                            Ethnicity                                    Design/Setting                      Sample Size      Age (Years)   Time Horizon (Years)                      Discrimination AUC                       Change from the Original AUC during Development         Calibration                   Reclassification             
  --------------------------------------------------------------- ----------------------------- ------------------------------------------------- -------------------------------------------- ------------------------------------------------ ------------------- ------------- ---------------------- ---------------------------------------------------------- ---------------------------------------------------- ---------------------- ---------------------------------------- ---------------------------------------
  Bang et al. 2007 [@pmed.1001344-Bang1]                                  SCORED score                           ARIC cohort/US                                      Mixed                           Prospective cohort/population-based              12,038           45--65                                                       0.71                                                   −0.17                                   NR                              NA                                      NA
  Bang et al. 2008 [@pmed.1001344-Bang2]                                  SCORED score             NHANES 2003--2004 survey/ARIC/CHS cohort/US                       Mixed                        Cross-sectional (NHANES)/population-based            4,298             ≥20                NA                                      0.88                                                     0                                     NR                              NA                                      NA
                                                                                                                                                                                                Prospective cohort (ARIC/CHS)/population-based        21,221             ≥45                5                                    0.78--0.80                                            −0.10 to −0.08                                                                                    
  Bang et al. 2009 [@pmed.1001344-Bang3]                                  SCORED score                     ENRICHD and VISP cohort/US                          Mixed/mainly White                      Cross sectional/population-based          2,145 for ENRICHD    Mean: 61              NA                                      0.75                                                   −0.13                                   NR                              NA                                      NA
                                                                                                                                                                                                                                                  3,640 for VISP      Mean: 66              NA                                      0.68                                                    −0.2                                                                                         
  Chien et al. 2010 [@pmed.1001344-Chien1]                              ARIC/CHS score 1                         Chinese/Taiwan                                      Asian                           Prospective cohort/population-based               5,168         Mean: 51.2             4                                       0.65                                                   −0.03                                   NR                              NA                                      NA
  Chien et al. 2010 [@pmed.1001344-Chien1]                              ARIC/CHS score 2                         Chinese/Taiwan                                      Asian                           Prospective cohort/population-based               5,168         Mean: 51.2             4                                       0.65                                                   −0.05                                   NR                              NA                                      NA
  Chien et al. 2010 [@pmed.1001344-Chien1]                              ARIC/CHS score 1                         Chinese/Taiwan                                      Asian                           Prospective cohort/population-based               5,168         Mean: 51.2             4                                       0.74                                                   +0.06                                   NR                              NA                                      NA
  Chien et al. 2010 [@pmed.1001344-Chien1]                              ARIC/CHS score 2                         Chinese/Taiwan                                      Asian                           Prospective cohort/population-based               5,168         Mean: 51.2             4                                       0.74                                                   +0.04                                   NR                              NA                                      NA
  Hippisley-Cox and Coupland 2010 [@pmed.1001344-HippisleyCox1]           QKidney score                          THIN Cohort/UK                    Mixed---white, black, South-Asian, Chinese        Prospective cohort/population-based             1,581,745         35--74               NR            CKD: 0.88, women; 0.88, men/ESRD: 0.82, women; 0.84, men   CKD: 0, women; 0, men/ESRD: 0.02, women; 0.01, men            NR                              NA                                      NA
  Collins and Altman 2012 [@pmed.1001344-Collins1]                        QKidney score                          THIN Cohort/UK                    Mixed---white, black, South-Asian, Chinese        Prospective cohort/population-based            1,6000,000         35--74              6.21                                 0.86 for CKD                                               −0.02                                   NR                              NA                                      NA
                                                                                                                                                                                                                                                                                                                               0.83 for ESRD                                               −0.01                                                                                         
  Chien et al. 2010 [@pmed.1001344-Chien1]                               Taiwan score 2          Chin-Shan Community Cardiovascular Cohort/China                    Chinese                          Prospective cohort/population-based               3,205             NR                2.2                                      0.67                                                    −0.1                          HL test (*p* = 0.85)   −0.0889 for adding biochemical factors   0.0141 for adding biochemical factors
  Blech et al. 2011 [@pmed.1001344-Blech1]                               Israel score 2                Independent (Ashkenazi Jews)/Israel                           White                               Cross-sectional/clinic-based                   906              NR                ---                                      0.57                                                   −0.06                                   NR                              NA                                      NA
  O\'Seaghdha et al. 2012 [@pmed.1001344-OSeaghdha2]                   Framingham score 4c                           ARIC/US                                    White and black                      Prospective cohort/population-based               1,777         Mean: 62.4            8.5                     0.75 in black individuals (*n* = 424)                                   −0.04                          HL test (*p* = 0.29)                     NA                                      NA
                                                                                                                                                                                                                                                                                                                  0.74 in white individuals (*n* = 1,353)                                  −0.05                          HL test (*p* = 0.01)                                           
  Kwon et al. 2012 [@pmed.1001344-Kwon1]                                Korean risk score         Korean Genome Epidemiology Study cohort/Korea                      Asian                             Cross-sectional/population-based                8,166             ≥30                NA                                      0.78                                                   −0.09                                   NR                              NA                                      NA

ARIC, Atherosclerosis Risk in Communities Study; CHS, Cardiovascular Health Study; HL, Hosmer-Lemeshow; NA, not applicable; NHANES, National Health and Nutrition Examination Survey; NR, not reported; THIN, The Health Improvement Network.

Risk Scores for Predicting Progression of CKD to ESRD {#s3b}
-----------------------------------------------------

[Table 3](#pmed-1001344-t003){ref-type="table"} shows the models for the prediction of progression to later stages among people with already established CKD. We found 17 CKD progression risk scores, developed from Cox regression models using data from clinical settings, mainly in white populations. Two of the CKD progression risk scores were developed from a cohort of people with type 2 diabetes and nephropathy [@pmed.1001344-Keane1],[@pmed.1001344-Desai1], and three other scores used cohorts of people exclusively with IgA nephropathy [@pmed.1001344-Goto1]--[@pmed.1001344-Wakai1]. The risk factors included in CKD progression risk models varied. The number of candidate variables tested for inclusion in the models ranged from ten to 24, corresponding to a ratio of number of observed events (outcome of interest) to number of candidate variables of four to 16. For one risk model, the performance in the derivation sample was not reported [@pmed.1001344-Keane1], although the performance of the score was later assessed in a validation study conducted in a different population. When evaluated, the C-statistic of these models ranged from 0.56 to 0.94, and calibration (reported for two models only) was good. In addition to reporting beta coefficients for regression models, four studies also provided a point-based scoring system [@pmed.1001344-Goto2]--[@pmed.1001344-Johnson1] or a risk calculator [@pmed.1001344-Landray1].

10.1371/journal.pmed.1001344.t003

###### Development of risk models for predicting the progression of chronic kidney disease.

![](pmed.1001344.t003){#pmed-1001344-t003-3}

  Study                                                                                  Country/Ethnicity                                                   Design/Setting                              Candidate Variables (*n*)                                                                                                        Risk Factors Included                                                                                                                *n* Total/*n* Outcomes           Age (Years)                                                               Outcomes                                                                Time Horizon (Years)[a](#nt105){ref-type="table-fn"}             Discrimination (AUC)                       Calibration            Method of Internal Validation          Type of Model
  --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------- ------------------------------- -------------------------------- ----------------------------
  Keane et al. 2006 [@pmed.1001344-Keane1]                               28 countries (Asia, Europe, America)/mainly white                           Prospective cohort/clinic-based                                29                                                                                                   Urinary ACR, serum albumin, serum creatinine, hemoglobin                                                                                        1,513 with T2DM and nephropathy/341      31--70                                         ESRD (need for long-term dialysis or renal transplantation)                                                              3.4                                               NR                                    NR                              None                           Cox
  Kent et al. 2007 [@pmed.1001344-Kent1]                           Multiple countries (Asia, Europe, North America)/mainly white                     Prospective cohort/clinic-based                                NR                                                                                                Age, gender, serum creatinine, urinary protein excretion, SBP                                                                                                     1,860                   Mean: 51.9    kidney disease progression (doubling in serum creatinine from baseline or kidney failure, defined as onset of long-term dialysis)                                                                            0.83                          HL test (*p* = 0.33)                   Apparent                         Cox
  Wakai et al. 2006 [@pmed.1001344-Wakai1]                                                  Japan/Asian                                              Prospective cohort/clinic-based                                NR                                                                                        Age, sex, SBP, proteinuria, hematuria, serum total protein, histological grade                                                                            2,269 people with IgA nephropathy/207      5--80                                                    ESRD (initiation of dialysis therapy)                                                                          7                                               0.94                                   NR                            Apparent                         Cox
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.95/0.93                                NR                 Linear interpolation/Bootstrap  
  Goto et al. 2009 [@pmed.1001344-Goto1]                                                    Japan/Asian                                              Prospective cohort/clinic-based                                17                                                                              Proteinuria, hypoalbuminemia, mild hematuria, serum total protein levels, DBP, histological grade                                                                    790 people with IgA nephropathy/68        \>13                                                Renal deterioration including chronic dialysis                                                                      10                               0.83, decision tree; 0.81, logistic                   NR                            Apparent              Decision tree and logistic
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    0.82, decision tree                           NR                           Bootstrap             
  Goto et al. 2009 [@pmed.1001344-Goto2]                                                    Japan/Asian                                              Prospective cohort/clinic-based                                10                                                                                      Sex, age, SBP, proteinuria, mild hematuria, serum albumin, GFR, histological grade                                                                          2,283 people with IgA nephropathy/252      5--80                                                    ESRD (initiation of dialysis therapy)                                                                          10                                              0.94                                   NR                            Apparent                         Cox
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.94                                   NR                           Bootstrap             
  Johnson et al. 2008 [@pmed.1001344-Johnson1]                                               US/mixed                                               Retrospective cohort/clinic-based                                6                                                                                                        Age, sex, eGFR, diabetes, anemia, hypertension                                                                                                          9,782/323                   30--89                             ESRD (renal replacement therapy in patients with stage 3 or 4 CKD \[MDRD defined\])                                                   5                                                NR                           HL test (*p* = 0.99)                   Apparent                         Cox
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.89                                   NR                           Bootstrap             
  Hallan et al. 2009 [@pmed.1001344-Hallan1]                                               Norway/white                                            Prospective cohort/population-based                              19                                                                                  Age, gender, physical activity, diabetes, SBP, antihypertensive medication, HDL, eGFR, ACR                                                                                   65,589/124                 Mean: 50.1                                                           ESRD (MDRD defined)                                                                                  10.3                                             0.86                                   NR                            Apparent                         Cox
  Landray et al. 2010 [@pmed.1001344-Landray1]---Landray model                         England/mainly white                                          Prospective cohort/clinic-based                                22                                                       Creatinine level, phosphate level, urinary ACR, female sex (ERSD prediction)/NT-pro-BNP, age, current smoking, increased TnT (death prediction)                                               382/190 (ERSD) and 150 (death)       Mean: 61.5                             ESRD (initiation of maintenance dialysis therapy or kidney transplant) or death                                        4.1 for ESRD and 6 for death                   0.87 for ESRD and 0.82 for death                     NR                            Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 1                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                                                           Age, sex                                                                                                                             3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.56                                   NR                            Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 2                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                                                        Age, sex, eGFR                                                                                                                          3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.89                      Modified HL test (*p*\<0.001)              Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 3                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                                                 Age, sex, eGFR, albuminuria                                                                                                                    3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.91                      Modified HL test (*p*\<0.001)              Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 4                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                                     Age, sex, eGFR, albuminuria, diabetes, hypertension                                                                                                        3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.91                                   NR                            Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tandri model 5                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                                        Age, sex, eGFR, albuminuria, SBP, DBP, weight                                                                                                           3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.92                                   NR                            Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 6                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                                                Age, sex, eGFR, albuminuria, serum albumin, serum phosphate, serum bicarbonate, serum calcium                                                                                   3,449/386                  Mean: 70         Kidney failure (need for dialysis or preemptive kidney transplantation) in patients with stage 3 to 5 CKD (MDRD defined)                                 5                                               0.92                      Modified HL test (*p*\<0.001)              Apparent                         Cox
  Tangri et al. 2011 [@pmed.1001344-Tangri1]---Tangri model 7                       Canada/mixed, mainly white                                       Prospective cohort/clinic-based                                24                                                               Age, sex, eGFR, albuminuria, serum albumin, diabetes, hypertension, SBP, DBP, serum phosphate, serum bicarbonate, serum calcium                                                                  3,449/386                  Mean: 70                                                               ESRD or death                                                                                      5                                               0.92                                   NR                            Apparent                         Cox
  Desai et al. 2011 [@pmed.1001344-Desai1]---TREAT ESRD model 1        US and Canada/mainly white, but also black and other        Prospective cohort (people with T2DM, CKD, and anemia)/clinic-based              35                       Age, sex, race, BMI, insulin use, eGFR, serum urea nitrogen, urinary protein-creatinine ratio, hemoglobin level, Hx of heart failure, Hx of stroke, Hx of PAD, Hx of arrhythmia, serum ferritin, CRP, Hx of AKI              995/222 ESRD (407 death or ESRD)       Mean: 68                                                               ESRD or death                                                                                     3.5                            0.84 for ESRD, and 0.75 for ESRD or death                NR                            Apparent                         Cox
  Desai et al. 2011 [@pmed.1001344-Desai1]---TREAT ESRD model 2        US and Canada/mainly white, but also black and other        Prospective cohort (people with T2DM, CKD and anemia)/clinic-based               37               Age, sex, race, BMI, insulin use, eGFR, serum urea nitrogen, urinary protein-creatinine ratio, hemoglobin level, Hx of heart failure, Hx of stroke, Hx of PAD, Hx of arrhythmia, serum ferritin, CRP, Hx of AKI, TnT, NT-pro-BNP     995/222 ESRD (407 death or ESRD)       Mean: 68                                                               ESRD or death                                                                                     3.5                            0.85 for ESRD, and 0.76 for ESRD or death                NR                            Apparent                         Cox

AKI, acute kidney injury; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; HL, Hosmer-Lemeshow; Hx, history; NT-pro-BNP, N-terminal pro--brain natriuretic peptide; PAD, peripheral arterial disease; NR, not reported; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TnT, Troponin T.

Time horizon is the time over which the prediction of outcomes is made, and is the duration of follow-up in each study unless specified otherwise.

As shown in [Table 4](#pmed-1001344-t004){ref-type="table"}, five of the CKD progression risk models were externally validated (C-statistic: 0.83 to 0.91); the change in C-statistic from the original value when the model was first developed ranged from −0.1 to +0.03. This change was negative in all but one case, thus indicating a generally poorer discrimination.

10.1371/journal.pmed.1001344.t004

###### External validation of risk models for predicting chronic kidney disease progression.
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  Study                                           Name of the Model Validated       Country/Ethnicity                Design/Setting            Sample Size   Mean Age (Years)     Time-Horizon (Years)                                             Discrimination AUC                                               Change from Original AUC                          Calibration                                                         Reclassification                                       
  ---------------------------------------------- ----------------------------- ---------------------------- --------------------------------- ------------- ------------------ --------------------------- --------------------------------------------------------------------------------------------------- ----------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------
  Landray et al. 2010 [@pmed.1001344-Landray1]           Landray model             England/mainly white      Prospective cohort/clinic-based       213             61.5         4.1 for ESRD, 6 for death                                     0.91 for ESRD, 0.82 for death                                        +0.03 for ESRD, 0 for death                            NR                                                                     NA                                                              NA
  Tangri et al. 2011 [@pmed.1001344-Tangri1]            Tangri model 2          Canada/mixed, mainly white   Prospective cohort/clinic-based      4,942             69                      5                                                             0.79                                                                −0.1                                        NR                                                                     NR                                                              NR
  Tangri et al. 2011 [@pmed.1001344-Tangri1]            Tangri model 3          Canada/mixed, mainly white   Prospective cohort/clinic-based      4,942             69                      5                                                             0.83                                                                −0.08                                       NR                                                                     NR                                               0.10 (42%) model 3 versus model 2
  Tangri et al. 2011 [@pmed.1001344-Tangri1]            Tangri model 6          Canada/mixed, mainly white   Prospective cohort/clinic-based      4,942             69                      5                                                             0.84                                                                −0.08                 Modified HL (Nam and D\'Agostino) statistic: 32                                              NR                                               0.02 (6%) model 3 versus model 6
  Tangri et al. 2011 [@pmed.1001344-Tangri1]            Tangri model 7          Canada/mixed, mainly white   Prospective cohort/clinic-based      4,942             69                      5                                                             0.84                                                                −0.08                                       NR                                                                     NR                                                              NR
  Desai et al. 2011 [@pmed.1001344-Desai1]             REENAL risk score        US and Canada/mainly white   Prospective cohort/clinic-based       995              68                     3.5              0.80 (0.81 when Troponin T and N-terminal pro--brain natriuretic peptide added to original model)   NA (as original AUC not reported)                         NR                          19 when Troponin T, and N-terminal pro--brain natriuretic peptide added to original model                  NR

HL, Hosmer-Lemeshow; NA, not applicable; NR, not reported.

Two studies investigated the improvement of three different CKD progression models [@pmed.1001344-Tangri1],[@pmed.1001344-Desai1], after adding biomarkers to traditional risk factors (serum bicarbonate and phosphate in one case [@pmed.1001344-Tangri1], and Troponin T plus brain natriuretic peptide in the two other cases) [@pmed.1001344-Desai1]. The change in C-statistic or AUC varied from 0.01 to 0.02, and NRI from 16.9% to 26.7%.

Impact Studies and Incorporation of CKD Prediction Models in Clinical Practice Guidelines {#s3c}
-----------------------------------------------------------------------------------------

We found no evidence in guidelines of recommendations for using CKD risk prediction models to estimate the risk in patients either in clinical or community settings. We also did not find any studies assessing the impact of adopting CKD (occurrence and progression) risk scores in clinical practice on the process of care and outcomes of patients.

Discussion {#s4}
==========

This systematic review shows that a sizeable number of renal risk prediction models have been developed, with, however, variation in their quality. Reasons for this may be specific to nephrology, where risk prediction is still in its infancy and the methodology for predictive research may be underappreciated. Despite the heterogeneity of CKD, with several specific forms, this review demonstrates the feasibility of defining individual renal risk using a combination of commonly assessed variables. Indeed, there was remarkable similarity between the variables that entered the prediction models ([Tables S1](#pmed.1001344.s001){ref-type="supplementary-material"} and [S2](#pmed.1001344.s002){ref-type="supplementary-material"}), each developed in a distinct group of participants, sometimes with specific forms of CKD. The discriminative performance of existing models was generally acceptable-to-good on the derivation sample. However, when corrected for overfitting (internal validation) or tested in a new population (external validation), this discriminative performance was modest-to-acceptable. For CKD risk prediction, the SCORED model appears to be the most reliable, as it is the most externally validated model, with a reasonable discrimination [@pmed.1001344-Bang1]. Regarding CKD progression, no risk model has been extensively validated in different populations.

Potential Public Health and Clinical Applications of CKD Risk Models {#s4a}
--------------------------------------------------------------------

Risk prediction models have potential applications in the prevention and management of CKD. Risk communication to patients may motivate them for lifestyle modification and adherence to prescribed therapies. Using models for predicting progression of CKD, clinicians may be able to tailor disease-modifying therapies as well as frequency of monitoring to individual risk. Indeed, therapies for controlling several variables included in CKD progression models (e.g., diabetes and hypertension) have been shown to delay CKD progression. Furthermore, using CKD progression models to identify patients who are most likely to need renal replacement therapy would allow patient education on available therapeutic options. CKD risk scores may be useful in the assessment of novel technologies or biomarkers for risk prediction, or for patient recruitment in prevention trials. They can also serve in mass screening and public education initiatives. For all these applications, estimates of CKD risk from prediction models must be accurate and validated.

Development of Existing CKD Risk Prediction Models {#s4b}
--------------------------------------------------

The performance of prediction models is largely determined by the appropriateness of the methodological approaches used to develop them. Virtually none of the existing CKD models was developed using data specifically collected for risk modeling purposes. This may raise concerns about the quality of the predictors and outcomes tested/included in the models, as well as the completeness of measurements. Lessons learned from CVD prediction suggest that the source of data for model development matters less, provided that the ensuing model can reliably predict the outcome of interest in different populations [@pmed.1001344-vanDieren1]. Indeed, in practice, assembling data only for the purpose of modeling can be challenging, and researchers tend to rely on available data collected for other reasons [@pmed.1001344-Moons1]. At least four of the models were likely statistically underpowered, based on having a ratio of the number of outcomes to the number of candidate predictors of \<8 [@pmed.1001344-Kwon1],[@pmed.1001344-Ando1],[@pmed.1001344-Desai1],[@pmed.1001344-Goto1],[@pmed.1001344-Hallan1]. The performance of such models tends to drop substantially when the model is applied to different populations [@pmed.1001344-Kwon1]. Other mistakes that affect model performance were present across studies, including dichotomization of continuous variables prior to modeling, linearity assumptions without formal testing, and exclusion of participants with missing values on predictor/outcome variables.

Internal Validation of Existing CKD Prediction Models {#s4c}
-----------------------------------------------------

One model was published without indicators of performance during the derivation process [@pmed.1001344-Keane1]. Most models provided measures of performance, which were based on the direct application of the model to the derivation sample (apparent performance). This approach is optimistic (self-fulfilling prophecy). Some models provided performance measures from internal split-sample or bootstrap validation, which may provide the new user with an idea about what to expect when applying the model to different populations. When reported, discrimination was always good for CKD progression models, and acceptable-to-good for prevalent/incident CKD models, indicating that these models were able to differentiate participants with CKD from those without in the derivation sample. Calibration, a key property of model performance, was less commonly assessed during the derivation process. Whether calibration performance of a model in one population can inform its behavior in another population is still debated. However, there is a growing agreement that, because calibration is largely affected by the background risk, which varies across populations, models need to be updated through recalibration procedures to provide accurate estimates of the risk in new populations. There have been attempts to update some of the existing CKD models, but the procedures used (addition of extra variables) have focused on improvement in discriminatory performance [@pmed.1001344-Chien1],[@pmed.1001344-Jardine1],[@pmed.1001344-Fox1],[@pmed.1001344-OSeaghdha1], and only one study reported change in the calibration properties [@pmed.1001344-Jardine1].

External Validation of Existing CKD Risk Prediction Models {#s4d}
----------------------------------------------------------

The demonstration of the performance of a model in new populations is an important step before recommending its widespread use. A limited number of existing CKD prediction models have been tested on different populations [@pmed.1001344-Bang1],[@pmed.1001344-Blech1],[@pmed.1001344-Chien1],[@pmed.1001344-OSeaghdha2]--[@pmed.1001344-Kshirsagar1],[@pmed.1001344-Landray1]. Validation studies have mainly been conducted by the same group of investigators who developed the models. This is methodologically inferior and quantitatively insufficient to provide good indicators of models\' behavior in various populations. Hence, more validation studies of existing models are needed, ideally by different investigators, to guarantee their generalizability to a larger number of people. Instead of developing new models for their own setting, investigators in the field of CKD may consider integrating aspects of the validation of existing models into future studies. In addition to providing indicators of the performance of existing models in various settings, such an approach limits unnecessary development of new models.

Implementation of Existing CKD Prediction Models {#s4e}
------------------------------------------------

CKD models have largely been published in the form of mathematical equations, with point-scoring systems [@pmed.1001344-Bang1],[@pmed.1001344-OSeaghdha2],[@pmed.1001344-Goto2]--[@pmed.1001344-Johnson1] or calculators [@pmed.1001344-Tangri1],[@pmed.1001344-HippisleyCox1],[@pmed.1001344-Landray1] for a few. The mathematical format may not be suitable for application in various settings, particularly by busy clinicians who may be less familiar with manipulating complex formulas. Translation efforts are therefore needed to convert accurate and validated CKD prediction equations into simple tools that can improve their uptake in various settings [@pmed.1001344-Tangri1]. Some context-specific efforts may also be required to derive appropriate cutoffs for defining high-risk status when models are integrated in guidelines for screening. It is, however, important to confirm whether the implementation of CKD risk prediction models affects the behavior of healthcare providers and improves outcomes of care. At present, no implementation study of CKD risk prediction models has been conducted.

Published studies have relied on GFR estimated from the MDRD equation to define CKD [@pmed.1001344-Levey2]. The MDRD equation provides less accurate estimates of GFR in different ethnic groups, compared with estimates derived from the more recent CKD-EPI equation [@pmed.1001344-Levey3], resulting in "over-diagnosis" of CKD using the MDRD equation. There have been suggestions that this over-diagnosis may have little effect on estimates of the association between risk factors and CKD outcomes [@pmed.1001344-Kwon1],[@pmed.1001344-OSeaghdha2] and, accordingly, on discriminatory performance when models developed to predict the outcome of CKD based on the MDRD equation are applied to the outcome of CKD based on the CKD-EPI formula. However, the difference in prevalence/incidence of CKD based on the two formulas will invite recalibration of MDRD equation--based models to improve their applicability with the increasing international adoption of CKD-EPI estimates of GFR for CKD diagnosis.

Participants in the reviewed studies were overwhelmingly white. A homogenous population does not allow researchers to probe into the whole scope of the variability in CKD risk. This is even more important for CKD than for other diseases, as some ethnic groups are particularly prone to CKD (e.g., African-Americans), and the use of risk stratification tools in these groups may be more warranted. Future studies should therefore incorporate more participants of different ethnic backgrounds.

Strengths and Limitations of the Review {#s4f}
---------------------------------------

The strengths of this review include the exclusion of studies that reported only effect estimates for independent association of risk factors with CKD. These measures alone provide no information on model calibration and global discriminative performance. The case for predictive testing depends not merely on the magnitude of the risk ratio, but also on the extent to which the test results are useful for improving prediction of disease when various risk factors are accounted for. This systematic review may also help policy makers decide whether to incorporate risk tools in guidelines for screening, routine evaluation, and management of CKD. Such an inclusion may be premature at this point in time, particularly in the absence of extensive external validation studies and impact analyses. We did not explicitly rank or categorize the quality of existing CKD risk models, mindful that there is no agreed-on scientific system for rating risk prediction model quality. Some will argue that minimizing risk for potential bias is of critical importance, while others might support the view that a risk score should be judged on its ability to perform accurately across diverse settings. Finally, our ability to assess publication bias was limited.

Conclusion {#s4g}
----------

This review suggests that risk models for predicting CKD or its progression have a modest-to-acceptable discriminatory performance, but would need to be better calibrated and externally validated---and the impact of their use on outcomes assessed---before these are incorporated in guidelines. Their potential application for screening or management to identify CKD in a heterogeneous population will also depend on the context. In the US, for example, the adoption of the Kidney Disease Outcomes Quality Initiative guidelines has led to systematic reporting of eGFR by laboratories whenever serum creatinine is requested. Consequently, a certain degree of de facto opportunistic CKD screening is happening. In such a context, risk scores for predicting CKD progression or outcomes would be particularly useful for defining prognosis in identified people. However, an important fraction of the population at high risk of CKD without access to care could still be identified in the community using CKD risk prediction tools.
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ACR

:   albumin/creatinine ratio

ADVANCE

:   Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation

AUC

:   area under the receiver operating characteristic curve

CKD

:   chronic kidney disease

CKD-EPI

:   Chronic Kidney Disease Epidemiology Collaboration

CVD

:   cardiovascular disease

eGFR

:   estimated glomerular filtration rate

ESRD

:   end-stage renal disease

GFR

:   glomerular filtration rate

IDI

:   integrated discrimination improvement index

MDRD

:   Modification of Diet in Renal Disease

NRI

:   net reclassification improvement
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